Author: Daniel Cameron
-
Where is the FDA test for relapsing fever spirochete, Borrelia miyamotoi?
If the FDA gets its way, physicians would only have access to diagnostic tests for tick borne diseases that are FDA approved. This would eliminate “specialty labs,” and severely restrict a clinicians ability to diagnose Lyme disease, as well as other tick-borne co-infections. This is a dangerous move in a period when we’re seeing an…
-
Lyme disease: One size does not fit all
A read of the International Lyme and Associated Diseases Society (ILADS) 2014 evidence based guidelines says otherwise. The ILADS guidelines focus on the risk of poor outcomes such as chronic neurologic Lyme disease, Lyme encephalopathy, and post-Lyme disease syndrome. The ILADS guidelines highlight the poor evidence using the Institute of Medicine’s recommended evidence grading system. The…
-
Obama plan to fight antibiotic resistance may limit treatment for Lyme disease
The task force by Executive Order must submit an action plan by February 15, 2015, outlining specific steps on how to implement a national strategy to combat antibiotic resistance and accelerate research and development on new antibiotics by 2020. The task force will be led by the secretaries of Health and Human Services, the Department…
-
Why ILADS 2014 treatment guidelines are important
The ILADS 2014 treatment guidelines for Lyme disease identified a number of key issues in making these recommendations: Lyme disease is a complex illness and patients may experience both acute and persistent manifestations Persistent manifestations may produce profound quality-of-life impairments, yet the mechanisms that produce persistent manifestations are poorly understood. The available evidence regarding the…